CAR-T cell therapy effective in therapy-resistant mantle cell lymphoma patients
Researchers have discovered that CD19-targeting CAR-T cell therapy may be effective in patients with relapsed mantle cell lymphoma that displayed resistance to prior therapies.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>